Table 3.

IRR and 95% CIs of outpatient visits (excluding routine follow-up visits for lymphoma) and inpatient visits and bed days during follow-up (from 1 year after diagnosis)

	IRR; 95% CI∗
	Total	1-5 y after diagnosis	5-10 y after diagnosis	>10 y after diagnosis
Outpatient visits
Comparators	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
MCL	2.0; 1.8-2.2	2.2; 2.0-2.5	2.1; 1.8-2.4	1.4; 1.1-1.8
Comparators	0.6; 0.5-0.6	0.5; 0.4-0.6	0.5; 0.4-0.6	0.6; 0.4-0.8
non–HD-ASCT	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
HD-ASCT†	1.2; 1.0-1.5	1.3; 1.0-1.6	1.1; 0.8-1.4	0.7; 0.5-1.1
Inpatient visits
Comparators	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
MCL	7.2; 6.3-8.3	8.7; 7.3-10.3	4.6; 3.7-5.8	2.6; 1.8-3.7
Comparators	0.1; 0.1-0.2	0.1; 0.1-0.1	0.2; 0.1-0.2	0.3; 0.2-0.5
non–HD-ASCT	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
HD-ASCT†	1.0; 0.7-1.3	1.0; 0.7-1.4	0.6; 0.4-0.9	0.5; 0.2-0.9
Bed days
Comparators	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
MCL	8.3; 6.8-10.1	10.0; 7.7-13.0	5.2; 3.7-7.3	4.1; 2.4-6.9
Comparators	0.1; 0.1-0.2	0.1; 0.1-0.1	0.2; 0.1-0.3	0.2; 0.1-0.4
non–HD-ASCT	1.0 (ref)	1.0 (ref)	1.0 (ref)	1.0 (ref)
HD-ASCT†	1.1; 0.7-1.6	1.1; 0.7-1.9	0.8; 0.4-1.5	0.7; 0.3-2.1

^∗Adjusted for age, sex, calendar year, CCI, and education.

^†Treated with HD-ASCT within 12 months from diagnosis.